Here's why Avita Medical Ltd shares have gone gangbusters this month

Avita Medical Ltd (ASX:AVH) shares are up 45% in October on the back of positive developments in the United States. Should you invest?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has certainly been a great month to be a shareholder of regenerative medicine company Avita Medical Ltd (ASX: AVH). Its shares have rocketed higher by over 11% today to 14.5 cents, bringing its return in October to an incredible 45%.

The cause for the rampant buying of its shares is largely the result of a promising announcement from the company last week.

That announcement revealed that the U.S. Food and Drug Administration (FDA) has approved a further increase in the number of patients that can be treated in the United States with its ReCell regenerative medical device under special compassionate use protocols.

ReCell is the company's lead product and is used in the treatment of a wide variety of burns, reconstructive, and cosmetic procedures.

This is the third expansion the FDA has given the company and allows it to treat up to 48 patients who have insufficient skin available for the standard skin grafting treatment of their injuries.

As well as increasing the patient numbers, the FDA has also increased the number of hospitals that can use the product to 15.

Avita CEO Adam Kelliher was evidentially pleased with the development. He stated:

"We welcome this compassionate use expansion, which will allow surgeons to further deploy our devices in the U.S. for patients who suffer extensive injuries, and are in a life-threatening condition. It underlines our key proposition, that ReCell is a safe, powerful and effective means of facilitating healing. Most of the cases to date have been in burns, indicating the growing interest we are seeing within the U.S. burns community for our unique approach."

Avita is seeking pre-market approval for ReCell and its fully enrolled clinical trial has involved seven leading US burns centres. Management expects to submit its clinical data package in early 2017, with an anticipated market approval later in the year.

According to biotech research firm BioNap, the potential worldwide market for ReCell is over US$1 billion per year in sales. Clearly Avita and ReCell have a bright future if all goes to plan, so it's no surprise to see its share price rocket this month.

It is of course early days and a quick look at its cash flow statement would indicate a further capital raising may be necessary in the year ahead. But I would suggest keeping a close eye on Avita, as it could well have the potential for significant growth in the future.

If this is a little too high risk for you then I would suggest taking a look at Sirtex Medical Limited (ASX: SRX) or Nanosonics Ltd (ASX: NAN) instead.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »